MCID: SYS001
MIFTS: 86

Systemic Lupus Erythematosus

Categories: Genetic diseases, Rare diseases, Nephrological diseases, Immune diseases, Bone diseases, Skin diseases

Aliases & Classifications for Systemic Lupus Erythematosus

MalaCards integrated aliases for Systemic Lupus Erythematosus:

Name: Systemic Lupus Erythematosus 54 38 12 25 51 71 29 3 14
Lupus Nephritis 54 12 50 52 42 14 69
Lupus Erythematosus, Systemic 12 42 69
Disseminated Lupus Erythematosus 12 25
Libman-Sacks Disease 25 69
Sle 25 71
Sle - Lupus Erythematosus, Systemic 12
Lupus Erythematosus Systemic 52
Lupus Erythematosus, Discoid 69
Lupus Erythematosus 69
Lupus Vulgaris 69
Le Syndrome 25
Lupus 25

Characteristics:

OMIM:

54
Inheritance:
autosomal dominant

Miscellaneous:
complement deficiency (e.g. c2 and c4 null alleles) are susceptible to developing sle
association between hla class ii alleles and presence of autoantibodies
onset between ages 16-55
female to male ratio 8-13:1


HPO:

32
systemic lupus erythematosus:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Systemic Lupus Erythematosus

NINDS : 51 Lupus (also called systemic lupus erythematosus) is a disorder of the immune system. Normally, the immune system protects the body against invading infections and cancers. In lupus, the immune system is over-active and produces increased amounts of abnormal antibodies that attack the body's tissues and organs. Lupus can affect many parts of the body, including the joints, skin, kidneys, lungs, heart, nervous system, and blood vessels. The signs and symptoms of lupus differ from person to person; the disease can range from mild to life threatening. Initial symptoms of lupus may begin with a fever, vascular headaches, epilepsy, or psychoses. A striking feature of lupus is a butterfly shaped rash over the cheeks. In addition to headache, lupus can cause other neurological disorders, such as mild cognitive dysfunction, organic brain syndrome, peripheral neuropathies, sensory neuropathy, psychological problems (including personality changes, paranoia, mania, and schizophrenia), seizures, transverse myelitis, and paralysis and stroke.

MalaCards based summary : Systemic Lupus Erythematosus, also known as lupus nephritis, is related to systemic lupus erythematosus 1 and rheumatoid arthritis, and has symptoms including seizures, thrombocytopenia and leukopenia. An important gene associated with Systemic Lupus Erythematosus is PTPN22 (Protein Tyrosine Phosphatase, Non-Receptor Type 22), and among its related pathways/superpathways are Systemic lupus erythematosus and Innate Immune System. The drugs Simvastatin and Everolimus have been mentioned in the context of this disorder. Affiliated tissues include Umbilical Cord, t cells and skin, and related phenotypes are hematopoietic system and immune system

NIH Rare Diseases : 50 lupus nephritis is a kidney disorder that is a complication of systemic lupus erythematous (sle), commonly known as lupus. the symptoms of lupus nephritis include blood in the urine, a foamy appearance to the urine, high blood pressure, and swelling in any part of the body. this condition typically occurs in people aged 20 to 40 years. treatment may involve medications to suppress the immune system, dialysis, or a kidney transplant. visit our web page on lupus for more information and resources. last updated: 11/24/2010

UniProtKB/Swiss-Prot : 71 Systemic lupus erythematosus: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

CDC : 3 Lupus occurs when an unknown trigger causes a person’s own immune system to attack their tissues, damaging the tissues and producing widespread inflammation. There is no known cause or cure for lupus; however, treatments are available.

Genetics Home Reference : 25 Systemic lupus erythematosus (SLE) is a chronic disease that causes inflammation in connective tissues, such as cartilage and the lining of blood vessels, which provide strength and flexibility to structures throughout the body. The signs and symptoms of SLE vary among affected individuals, and can involve many organs and systems, including the skin, joints, kidneys, lungs, central nervous system, and blood-forming (hematopoietic) system. SLE is one of a large group of conditions called autoimmune disorders that occur when the immune system attacks the body's own tissues and organs.

OMIM : 54
Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by production of autoantibodies against nuclear, cytoplasmic, and cell surface molecules that transcend organ-specific boundaries. Tissue deposition of antibodies or immune complexes induces inflammation and subsequent injury of multiple organs and finally results in clinical manifestations of SLE, including glomerulonephritis, dermatitis, thrombosis, vasculitis, seizures, and arthritis. Evidence strongly suggests the involvement of genetic components in SLE susceptibility (summary by Oishi et al., 2008). (152700)

Disease Ontology : 12 A lupus erythematosus that is an inflammation of connective tissue marked by skin rashes, joint pain and swelling, inflammation of the kidneys and inflammation of the tissue surrounding the heart.

Wikipedia : 72 Systemic lupus erythematosus (SLE), also known simply as lupus, is an autoimmune disease in which the... more...

Related Diseases for Systemic Lupus Erythematosus

Diseases in the Lupus Erythematosus family:

Systemic Lupus Erythematosus Systemic Lupus Erythematosus 14
Systemic Lupus Erythematosus 9 Systemic Lupus Erythematosus 1
Systemic Lupus Erythematosus 11 Systemic Lupus Erythematosus 2
Systemic Lupus Erythematosus 16 Systemic Lupus Erythematosus 3
Systemic Lupus Erythematosus 13 Systemic Lupus Erythematosus 10
Systemic Lupus Erythematosus 12 Systemic Lupus Erythematosus 4
Systemic Lupus Erythematosus 5 Systemic Lupus Erythematosus 7
Systemic Lupus Erythematosus 8 Systemic Lupus Erythematosus 15
Cr2-Related Susceptibility to Systemic Lupus Erythematosus Dnase1-Related Susceptibility to Systemic Lupus Erythematosus
Itgam-Related Susceptibility to Systemic Lupus Erythematosus

Diseases related to Systemic Lupus Erythematosus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 799)
id Related Disease Score Top Affiliating Genes
1 systemic lupus erythematosus 1 35.6 TLR5 TREX1
2 rheumatoid arthritis 32.8 CD40LG CTLA4 IL10 PTPN22 STAT4
3 lymphoma 32.2 CD40LG CTLA4 IL10 SSB TLR9 TRIM21
4 myasthenia gravis 32.1 CD40LG FCGR2B PTPN22
5 malaria 31.4 CD40LG CR1 CTLA4 FCGR2A FCGR2B IL10
6 granuloma annulare 31.2 C4A C4B CD40LG CR1 TLR9
7 pseudohypoparathyroidism 31.1 CD40LG CTLA4 IL10 PTPN22 STAT4 TLR9
8 facial paralysis 30.7 CD40LG IL10
9 systemic lupus erythematosus 16 12.6
10 systemic lupus erythematosus 2 12.4
11 systemic lupus erythematosus 10 12.4
12 systemic lupus erythematosus 9 12.4
13 pediatric systemic lupus erythematosus 12.3
14 systemic lupus erythematosus 11 12.3
15 systemic lupus erythematosus 3 12.2
16 systemic lupus erythematosus 12 12.2
17 systemic lupus erythematosus 4 12.2
18 systemic lupus erythematosus 5 12.2
19 lupus erythematosus 12.2
20 systemic lupus erythematosus with nephritis 3 12.1
21 systemic lupus erythematosus with nephritis 2 12.1
22 systemic lupus erythematosus 14 12.1
23 systemic lupus erythematosus 13 12.1
24 systemic lupus erythematosus 7 12.1
25 systemic lupus erythematosus 8 12.1
26 systemic lupus erythematosus with nephritis 1 12.1
27 systemic lupus erythematosus 15 12.1
28 neonatal systemic lupus erythematosus 12.0
29 cr2-related susceptibility to systemic lupus erythematosus 12.0
30 dnase1-related susceptibility to systemic lupus erythematosus 12.0
31 itgam-related susceptibility to systemic lupus erythematosus 12.0
32 systemic lupus erythematous, association with 6 11.7
33 vitiligo-associated multiple autoimmune disease susceptibility 1 11.6
34 c1q deficiency 11.6
35 mixed connective tissue disease 11.5
36 neonatal lupus erythematosus 11.5
37 pure red-cell aplasia 11.3
38 humero-ulnar synostosis 11.3 C4A C4B PTPN22 STAT4
39 drug-induced lupus erythematosus 11.3
40 sjogren's syndrome 11.3
41 macrophage activation syndrome 11.3
42 macroglobulinemia, waldenstrom 1 11.3 CTLA4 IL10 PTPN22 STAT4
43 epidermolysis bullosa acquisita 11.3
44 collagen disease 11.3
45 combined cellular and humoral immune defects with granulomas 11.3 CTLA4 IL10 PTPN22
46 undifferentiated connective tissue disease 11.3
47 dermatomycosis 11.3 C4A C4B CD40LG
48 rapidly progressive glomerulonephritis 11.3
49 c3 deficiency 11.3
50 c1s deficiency 11.3

Comorbidity relations with Systemic Lupus Erythematosus via Phenotypic Disease Network (PDN): (show all 20)


Acute Cystitis Chronic Kidney Failure
Chronic Myocardial Ischemia Deficiency Anemia
Esophagitis Familial Atrial Fibrillation
Heart Disease Hypersensitivity Vasculitis
Hypertension, Essential Hypothyroidism
Intermediate Coronary Syndrome Ischemic Heart Disease
Mitral Valve Disease Neutropenia
Osteoporosis Postinflammatory Pulmonary Fibrosis
Raynaud Disease Rheumatoid Arthritis
Sjogren's Syndrome Systemic Scleroderma

Graphical network of the top 20 diseases related to Systemic Lupus Erythematosus:



Diseases related to Systemic Lupus Erythematosus

Symptoms & Phenotypes for Systemic Lupus Erythematosus

Symptoms via clinical synopsis from OMIM:

54

Neurologic- Central Nervous System:
seizures
psychosis

Skin Nails & Hair- Skin:
photosensitivity
erythematous malar rash
discoid rash

Respiratory- Lung:
pleuritis

Skeletal- Limbs:
arthritis

Laboratory- Abnormalities:
antiphospholipid antibody
anti dsdna antibody
serum antinuclear antibody

Hematology:
thrombocytopenia
leukopenia
hemolytic anemia

Cardiovascular- Heart:
pericarditis

Genitourinary- Kidneys:
nephritis

Immunology:
systemic lupus erythematosus


Clinical features from OMIM:

152700

Human phenotypes related to Systemic Lupus Erythematosus:

32 (show all 13)
id Description HPO Frequency HPO Source Accession
1 seizures 32 HP:0001250
2 thrombocytopenia 32 HP:0001873
3 leukopenia 32 HP:0001882
4 pericarditis 32 HP:0001701
5 pleuritis 32 HP:0002102
6 nephritis 32 HP:0000123
7 arthritis 32 HP:0001369
8 psychosis 32 HP:0000709
9 hemolytic anemia 32 HP:0001878
10 systemic lupus erythematosus 32 HP:0002725
11 cutaneous photosensitivity 32 HP:0000992
12 antinuclear antibody positivity 32 HP:0003493
13 antiphospholipid antibody positivity 32 HP:0003613

UMLS symptoms related to Systemic Lupus Erythematosus:


cyanosis, exanthema, icterus, pruritus, lupus-like rash, seizures

MGI Mouse Phenotypes related to Systemic Lupus Erythematosus:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.31 C4B CD40LG CTLA4 DNASE1 FCGR2A FCGR2B
2 immune system MP:0005387 10.22 TLR5 TLR9 TNFSF4 TREX1 TRIM21 C4B
3 homeostasis/metabolism MP:0005376 10.21 C4B CD40LG CTLA4 DNASE1 FCGR2B IL10
4 cardiovascular system MP:0005385 10.18 C4B CD40LG CTLA4 FCGR2B IL10 PDCD1
5 endocrine/exocrine gland MP:0005379 10.09 CD40LG CTLA4 FCGR2B IL10 PDCD1 PTPN22
6 digestive/alimentary MP:0005381 10.06 PTPN22 TLR5 TLR9 TREX1 C4B CTLA4
7 mortality/aging MP:0010768 10.03 TREX1 C4B CD40LG CTLA4 DNASE1 FCGR2A
8 liver/biliary system MP:0005370 9.86 C4B CTLA4 FCGR2B IL10 PDCD1 PTPN22
9 renal/urinary system MP:0005367 9.65 C4B CD40LG DNASE1 FCGR2B PDCD1 PTPN22
10 respiratory system MP:0005388 9.17 CTLA4 FCGR2B IL10 PDCD1 PTPN22 TLR5

Drugs & Therapeutics for Systemic Lupus Erythematosus

Drugs for Systemic Lupus Erythematosus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 364)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4,Phase 1,Early Phase 1 79902-63-9 54454
2
Everolimus Approved Phase 4,Phase 2 159351-69-6 6442177
3
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
5
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 128794-94-5 5281078
6
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 24280-93-1 446541
7
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
8
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 53-03-2 5865
9
Sirolimus Approved, Investigational Phase 4,Phase 2 53123-88-9 5284616 6436030 46835353
10
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
11
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 50-18-0, 6055-19-2 2907
12
Hydroxychloroquine Approved Phase 4,Phase 3,Phase 1,Phase 2 118-42-3 3652
13
belimumab Approved Phase 4,Phase 3,Phase 2,Phase 1 356547-88-1 5957 10451420
14
Pioglitazone Approved, Investigational Phase 4,Phase 1,Phase 2 111025-46-8 4829
15
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-78-2 2244
16
Azathioprine Approved Phase 4,Phase 3,Phase 2,Phase 1 446-86-6 2265
17
Cilostazol Approved Phase 4 73963-72-1 2754
18
Lenalidomide Approved Phase 4 191732-72-6 216326
19
Metformin Approved Phase 4 657-24-9 14219 4091
20
Sulfamethoxazole Approved Phase 4 723-46-6 5329
21
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
22
Thioguanine Approved Phase 4 154-42-7 2723601
23
Vincristine Approved, Investigational Phase 4 2068-78-2, 57-22-7 5978
24
Calcitriol Approved, Nutraceutical Phase 4,Phase 2 32222-06-3 134070 5280453
25
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
26
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
27
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2 58-05-9 143 6006
28
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2,Phase 1 50-14-6 5280793
29
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 1406-16-2
30 Anticholesteremic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
31 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
32 Calcium, Dietary Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
33 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
34 Hypolipidemic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
35 Lipid Regulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
36 Rosuvastatin Calcium Phase 4,Phase 2,Phase 1 147098-20-2
37 Vaccines Phase 4,Phase 2,Phase 3,Phase 1
38 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
39 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
40 Antiemetics Phase 4,Phase 2,Phase 3,Phase 1
41 Antifungal Agents Phase 4,Phase 2,Phase 1
42 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1
45 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1
46 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
47 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1
48 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 558)

id Name Status NCT ID Phase Drugs
1 Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease Unknown status NCT00188188 Phase 4 quinipril
2 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
3 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
4 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Unknown status NCT00815282 Phase 4 Human papilloma virus vaccine (cervarix)
5 Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant Unknown status NCT02084446 Phase 4 Everolimus;Very Low Tacrolimus;Low Tacrolimus;Steroids;Thymoglobulin;Sodium Mycophenolate
6 The Reduction of Systemic Lupus Erythematosus Flares :Study PLUS Completed NCT00413361 Phase 4 versus hydroxychloroquine
7 A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01597492 Phase 4
8 Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus Completed NCT00668330 Phase 4 Ibandronate+alfacalcidol+calcium;placebo ibandronate+alfacalcidol+calcium
9 Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus Completed NCT01322308 Phase 4 pioglitazone;placebo
10 Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus Completed NCT00371501 Phase 4 Rosuvastatin;placebo;aspirin;placebo
11 Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis Completed NCT00125307 Phase 4 tacrolimus
12 Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus Completed NCT01769937 Phase 4 H.P. Acthar Gel
13 Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With SLE: a Controlled Study Completed NCT00911521 Phase 4 human papillomavirus vaccination (Gardasil)
14 Mycophenolate Mofetil in Systemic Lupus Erythematosus (MISSILE) Completed NCT01101802 Phase 4 Mycophenolate mofetil;sugar pill
15 Effect of Hormone Replacement Therapy on Lupus Activity Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
16 Efficacy of Fish Oil in Lupus Patients Completed NCT00828178 Phase 4 Omega-3
17 Lupus Atherosclerosis Prevention Study Completed NCT00120887 Phase 4 Atorvastatin
18 Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Extra-renal Lupus Manifestations Completed NCT01112215 Phase 4 Azathioprine;Enteric-Coated Mycophenolate Sodium
19 Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis Completed NCT01206569 Phase 4 Long-acting tacrolimus (Advagraf, Astellas Pharma)
20 Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Completed NCT00048776 Phase 4 Pletal
21 Study To Evaluate The Safety And Efficacy Of Lenalidomide For Refractory Cutaneous Lupus Completed NCT01408199 Phase 4 Lenalidomide
22 The Effect of Metformin on Reducing Lupus Flares Recruiting NCT02741960 Phase 4 metformin;placebo
23 Acthar SLE (Systemic Lupus Erythematosus) Recruiting NCT02779153 Phase 4 Acthar low dose (40 U);Acthar high dose (80 U)
24 A Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Active Systemic Lupus Erythematosus (SLE) Recruiting NCT02953821 Phase 4 Repository corticotropin injection;Placebo gel
25 Safety and Immunogenicity of a Zoster Vaccine in SLE Recruiting NCT02477150 Phase 4
26 Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy Recruiting NCT02270970 Phase 4
27 Prophylactic Trimethoprim/Sulfamethoxazole to Prevent Severe Infections in Patients With Lupus Erythematous Recruiting NCT03042260 Phase 4 Trimethoprim-Sulfamethoxazole;Placebo Oral Tablet
28 A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE Recruiting NCT03098823 Phase 4 RAYOS;Prednisone
29 ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis Recruiting NCT01926054 Phase 4 Acthar gel
30 ACTHar in the Treatment of Lupus Nephritis Recruiting NCT02226341 Phase 4 CellCept;ACTHar gel;ACTHar gel
31 Low-dose VS High-dose IV Cyclophosphamide for Proliferative LN in Children Recruiting NCT01861561 Phase 4 Low-dose intravenous cyclophosphamide;High-dose intravenous cyclophosphamide
32 Thiopurine Induced Pancreatitis in IBD Patients Recruiting NCT02281799 Phase 4 Azathioprine
33 Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE) Active, not recruiting NCT01632241 Phase 4 Standard therapy
34 Acthar for the Treatment of Systemic Lupus Erythematosus in Patients With a History of Persistently Active Disease Active, not recruiting NCT01753401 Phase 4 Acthar;Placebo for Acthar
35 Belimumab Assessment of Safety in SLE Active, not recruiting NCT01705977 Phase 4
36 Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases Not yet recruiting NCT03122431 Phase 4 Thalidomide;Hydroxychloroquine reduced;Hydroxychloroquine high
37 Study Title: Assess the Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease Not yet recruiting NCT03287635 Phase 4 H.P Acthar Gel 80Unit/Ml Repository Injection
38 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Not yet recruiting NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
39 Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus (0733-271)(TERMINATED) Terminated NCT00739050 Phase 4 simvastatin;Comparator: Placebo
40 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
41 Levothyroxine in Pregnant SLE Patients Withdrawn NCT01276782 Phase 4 Levothyroxine
42 The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria Withdrawn NCT00508898 Phase 4 Calcitriol;Multivitamin
43 The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients Withdrawn NCT01359826 Phase 4 Milnacipran
44 Study of GL701 in Men With Systemic Lupus Erythematosus Unknown status NCT00037128 Phase 3 GL701
45 An Open Labeled Pilot Study of Atorvastatin in Systemic Lupus Erythematosus Unknown status NCT00432354 Phase 2, Phase 3 atorvastatin
46 To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids Unknown status NCT00053560 Phase 3 Prasterone (GL701)
47 GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids Completed NCT00082511 Phase 3 Prasterone (GL701)
48 A Study of Belimumab in Subjects With Systemic Lupus Erythematosus Completed NCT00410384 Phase 3 Placebo;Belimumab 1 mg/kg;Belimumab 10 mg/kg
49 A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT00424476 Phase 3 Placebo;Belimumab 1 mg/kg;Belimumab 10 mg/kg
50 A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01484496 Phase 3 Standard therapy

Search NIH Clinical Center for Systemic Lupus Erythematosus

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Systemic Lupus Erythematosus cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: lupus nephritis

Genetic Tests for Systemic Lupus Erythematosus

Genetic tests related to Systemic Lupus Erythematosus:

id Genetic test Affiliating Genes
1 Systemic Lupus Erythematosus 29

Anatomical Context for Systemic Lupus Erythematosus

MalaCards organs/tissues related to Systemic Lupus Erythematosus:

39
T Cells, Skin, Kidney, B Cells, Heart, Endothelial, Bone
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Systemic Lupus Erythematosus:
id Tissue Anatomical CompartmentCell Relevance
1 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Systemic Lupus Erythematosus

Articles related to Systemic Lupus Erythematosus:

(show top 50) (show all 5240)
id Title Authors Year
1
Association of anti-triosephosphate isomerase antibodies with aseptic meningitis in patients with neuropsychiatric systemic lupus erythematosus. ( 28451873 )
2017
2
Splenic calcification in systemic lupus erythematosus. ( 28939622 )
2017
3
Osteoporotic fractures in patients with systemic lupus erythematosus and end stage renal disease. ( 28530467 )
2017
4
Case of Pediatric Bullous Systemic Lupus Erythematosus Treated with Intravenous Immunoglobulin. ( 27778386 )
2017
5
Acute acalculous cholecystitis in patients with systemic lupus erythematosus: A unique form of disease flare. ( 28355987 )
2017
6
Socioeconomic consequences of systemic lupus erythematosus. ( 28520683 )
2017
7
Plasma ficolin levels and risk of nephritis in Danish patients with systemic lupus erythematosus. ( 27981461 )
2017
8
Acquired hemophilia as initial presentation in a patient with Systemic Lupus Erythematosus. ( 28523993 )
2017
9
Cerebral Venous Sinus Thrombosis Presenting Feature of Systemic Lupus Erythematosus. ( 28065614 )
2017
10
Characterization of patients with systemic lupus erythematosus who meet the diagnostic criteria for TAFRO syndrome. ( 28820362 )
2017
11
Systemic lupus erythematosus, following prodromal idiopathic thrombocytopenic purpura, presenting with skin lesions resembling malignant atrophic papulosis. ( 28691162 )
2017
12
What Can We Do When All Collapses? Fatal Outcome of Collapsing Glomerulopathy and Systemic Lupus Erythematosus With Diffuse Alveolar Hemorrhage: Case Report. ( 28457424 )
2017
13
P-glycoprotein gene MDR1 polymorphisms and susceptibility to systemic lupus erythematosus in Guangxi population: a case-control study. ( 28154898 )
2017
14
The Systemic Lupus Erythematosus-Associated Single Nucleotide Polymorphism rs1143678 in Integrin I+M Cytoplasmic Tail Generates a 14-3-3IP Binding Site That Is Proinflammatory. ( 27974454 )
2017
15
SLAMF7 engagement restores defective effector CD8+ T cells activity in response to foreign antigens in systemic lupus erythematosus. ( 28076903 )
2017
16
MALT lymphoma arising on a background of reactive pulmonary lymphoid hyperplasia in a patient with Systemic Lupus Erythematosus. ( 28945277 )
2017
17
Role of Angiography in Systemic Lupus Erythematosus-Induced Choroiditis. ( 28362518 )
2017
18
Systemic lupus erythematosus with ADAMTS13 inhibitor-negative thrombotic microangiopathy treated with combination of mycophenolate mofetil, plasma exchange and steroid. ( 27416846 )
2017
19
Successful treatment using corticosteroid combined antibiotic for acute acalculous cholecystitis patients with systemic lupus erythematosus. ( 28682919 )
2017
20
Bone Disease in Connective TissueA Disease/Systemic Lupus Erythematosus. ( 28900675 )
2017
21
Anti-neutrophil cytoplasmic antibodies in new-onset systemic lupus erythematosus. ( 28954092 )
2017
22
Estrogen receptor alpha gene ( ESR1) polymorphism can contribute to clinical findings in systemic lupus erythematosus patients. ( 27681518 )
2017
23
Efficacy and Safety of Rituximab in the Management of Pediatric Systemic Lupus Erythematosus: A Systematic Review. ( 28602379 )
2017
24
Mycobacterium avium Complex Septic Arthritis Presenting as Osteonecrosis of the Femoral Head in a Patient With Systemic Lupus Erythematosus. ( 28056158 )
2017
25
Serum Adiponectin Levels in Patients With Systemic Lupus Erythematosus: A Meta-analysis. ( 28937500 )
2017
26
Atypical Trigeminal Neuralgia: A Rare Neurological Manifestation of Systemic Lupus Erythematosus. ( 28077839 )
2017
27
Interferon-I+ coincides with suppressed levels of pentraxin-3 (PTX3) in systemic lupus erythematosus and regulates leucocyte PTX3 in vitro. ( 28257596 )
2017
28
Pneumococcal infection in patients with systemic lupus erythematosus. ( 28529115 )
2017
29
The association between systemic lupus erythematosus and bipolar disorderA -A a big data analysis. ( 28525775 )
2017
30
Association of novel polymorphisms in TMEM39A gene with systemic lupus erythematosus in a Chinese Han population. ( 28427360 )
2017
31
Tjalma syndrome (pseudo-pseudo Meigs') as initial manifestation of juvenile-onset systemic lupus erythematosus. ( 28522234 )
2017
32
Association Between TNF-I+ Promoter -308 A/G Polymorphism and Systemic Lupus Erythematosus Susceptibility: A Case-Control Study and Meta-Analysis. ( 27943420 )
2017
33
Severely Crusted Cheilitis as an Initial Presentation of Systemic Lupus Erythematosus. ( 28794568 )
2017
34
Central nervous system vasculitis in systemic lupus erythematosus: a case series report in a tertiary referral centre. ( 28420057 )
2017
35
Pulse dose steroids in severe pulmonary arterial hypertension secondary to systemic lupus erythematosus. ( 28515936 )
2017
36
Serum interleukin-17 in Egyptian children with systemic lupus erythematosus: is it related to pulmonary affection? ( 27587461 )
2017
37
Eyelash Trichomegaly: A Rare Presenting Feature of Systemic Lupus Erythematosus. ( 28839394 )
2017
38
Serum Adiponectin Levels in Patients With Systemic Lupus Erythematosus: A Meta-analysis. ( 28937471 )
2017
39
Increased risk of hepatitis B virus reactivation in systemic lupus erythematosus patients receiving immunosuppressants: a retrospective cohort study. ( 28534427 )
2017
40
No association of single nucleotide polymorphisms within H19 and HOX transcript antisense RNA (HOTAIR) with genetic susceptibility to systemic lupus erythematosus, rheumatoid arthritis, and primary SjAPgren's syndrome in a Chinese Han population. ( 28914367 )
2017
41
Internal Carotid Artery Occlusion in Systemic Lupus Erythematosus as a Potential Mimicker of Multiple Sclerosis. ( 28559831 )
2017
42
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. ( 28935492 )
2017
43
Macrophage activation syndrome at the onset of glucocorticoid-resistant systemic lupus erythematosus: a case report. ( 28918421 )
2017
44
Carotid intima-media thickness and arterial stiffness in pediatric systemic lupus erythematosus. ( 28420050 )
2017
45
Cortical Blindness in Systemic Lupus Erythematosus: The Blind Wolf. ( 28937478 )
2017
46
Atypical bone change of spine caused by epidural venous thrombosis in systemic lupus erythematosus with antiphospholipid syndrome. ( 28063414 )
2017
47
Systemic lupus erythematosus patients with high disease activity are associated with accelerated incidence of osteonecrosis: a systematic review and meta-analysis. ( 28948379 )
2017
48
The expression of interleukin-17 in cutaneous lesions of lupus erythematosus in pediatric-onset systemic lupus erythematosus. ( 28937401 )
2017
49
Assessment of the Hospital Anxiety and Depression Scale (HADS) performance for the diagnosis of anxiety in patients with systemic lupus erythematosus. ( 28940018 )
2017
50
Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: A study of 103 episodes in 89 adult patients. ( 28483541 )
2017

Variations for Systemic Lupus Erythematosus

UniProtKB/Swiss-Prot genetic disease variations for Systemic Lupus Erythematosus:

71
id Symbol AA change Variation ID SNP ID
1 PTPN22 p.Arg620Trp VAR_022605 rs2476601
2 TREX1 p.Arg169His VAR_028319 rs72556554
3 TREX1 p.Ala213Val VAR_037949 rs762011967
4 TREX1 p.Gly282Ser VAR_037950 rs113107733
5 TREX1 p.Arg295Ser VAR_037951 rs72556555
6 TREX1 p.Ala302Pro VAR_037952 rs112741962
7 TREX1 p.Pro345Leu VAR_037954 rs148833270
8 TREX1 p.Tyr360Cys VAR_037955 rs370504038
9 TREX1 p.Gly361Ala VAR_037956 rs780022923
10 TREX1 p.Asp255His VAR_070901

ClinVar genetic disease variations for Systemic Lupus Erythematosus:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 TREX1 NM_033629.4(TREX1): c.341G> A (p.Arg114His) single nucleotide variant risk factor rs72556554 GRCh37 Chromosome 3, 48508395: 48508395

Copy number variations for Systemic Lupus Erythematosus from CNVD:

7 (show all 43)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14694 1 110000000 163800000 Gain or loss FCGR3B Systemic lupus erythematosus
2 21050 1 156500000 165500000 Copy number FCGR3B Systemic lupus erythematosus
3 21051 1 156500000 165500000 Copy number FCGR3B Systemic lupus erythematosus
4 21053 1 156500000 165500000 Copy number FCGR3B Systemic lupus erythematosus
5 21628 1 159859611 159867782 Copy number FCGR3B Systemic lupus erythematosus
6 21630 1 159859611 159867782 Low copy number FCGR3B Systemic lupus erythematosus
7 21794 1 161592989 161601158 Copy number FCGR3B Systemic lupus erythematosus
8 21797 1 161592989 161601158 Deletion FCGR3B Systemic lupus erythematosus
9 107133 17 1225928 31649829 Copy number CCL3L3 Systemic lupus erythematosus
10 107143 17 1225928 31649843 Copy number CCL3L1 Systemic lupus erythematosus
11 107163 17 1242109 31665953 Copy number CCL4L2 Systemic lupus erythematosus
12 110232 17 31562580 31665959 Copy number CCL4L1 Systemic lupus erythematosus
13 110282 17 31800000 38100000 Copy number CCL3L1 Systemic lupus erythematosus
14 110283 17 31800000 38100000 Copy number CCL3L1 Systemic lupus erythematosus
15 110288 17 31800000 38100000 Copy number CCL4L1 Systemic lupus erythematosus
16 112168 17 38100000 38400000 Copy number CCL3L1 Systemic lupus erythematosus
17 113342 17 43165608 43178484 Amplification T-bet Systemic lupus erythematosus
18 162470 22 21800000 24300000 Gain or loss GSTT1 Systemic lupus erythematosus
19 186012 4 2713184 2727859 Deletion TNIP2 Systemic lupus erythematosus
20 196060 5 158674368 158690059 Amplification IL-12B Systemic lupus erythematosus
21 204042 6 105500000 114600000 Copy number C4A Systemic lupus erythematosus
22 204043 6 105500000 114600000 Copy number C4B Systemic lupus erythematosus
23 207132 6 15200000 46200000 Copy number Systemic lupus erythematosus
24 209409 6 2614953 31491069 Copy number MICA Systemic lupus erythematosus
25 210235 6 29900000 36800000 Low copy numbers C4 Systemic lupus erythematosus
26 210494 6 30400000 36600000 Copy number C4A Systemic lupus erythematosus
27 210495 6 30400000 36600000 Copy number C4B Systemic lupus erythematosus
28 210499 6 30400000 36600000 Copy number C4A Systemic lupus erythematosus
29 210506 6 30400000 36600000 Copy number C4B Systemic lupus erythematosus
30 210507 6 30400000 36600000 Copy number C4B Systemic lupus erythematosus
31 210512 6 30400000 36600000 Gain C4A Systemic lupus erythematosus
32 210513 6 30400000 36600000 Gain C4B Systemic lupus erythematosus
33 211033 6 31949833 32003194 Copy number C4A Systemic lupus erythematosus
34 211045 6 3197570 32111174 Copy number C4A Systemic lupus erythematosus
35 211049 6 3197570 32111174 Duplication C4 Systemic lupus erythematosus
36 211054 6 31982571 32003194 Copy number C4B Systemic lupus erythematosus
37 211360 6 32593131 32665540 Copy number HLA-DRB5 Systemic lupus erythematosus
38 212285 6 3674895 32665540 Copy number HLA-DRB1 Systemic lupus erythematosus
39 212431 6 3795995 32719407 Copy number HLA-DQA1 Systemic lupus erythematosus
40 212452 6 3813334 32742444 Copy number HLA-DQB1 Systemic lupus erythematosus
41 212671 6 40500000 46200000 Copy number Systemic lupus erythematosus
42 212678 6 40500000 93100000 Copy number Systemic lupus erythematosus
43 243031 8 7752198 7754236 Copy number DEFB4 Systemic lupus erythematosus

Expression for Systemic Lupus Erythematosus

LifeMap Discovery
Genes differentially expressed in tissues of Systemic Lupus Erythematosus patients vs. healthy controls: 35 (show all 12)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1 IFI27 interferon, alpha-inducible protein 27 Blood + 5.47 0.000
2 OTOF otoferlin Blood + 5.25 0.000
3 RPS4Y1 ribosomal protein S4, Y-linked 1 Blood - 4.40 0.000
4 IFIT1 interferon-induced protein with tetratricopeptide repeats 1 Blood + 4.22 0.000
5 LINC00661 long intergenic non-protein coding RNA 661 Blood + 4.15 0.000
6 SIGLEC1 sialic acid binding Ig-like lectin 1, sialoadhesin Blood + 4.12 0.000
7 EIF1AY eukaryotic translation initiation factor 1A, Y-linked Blood - 3.96 0.000
8 RSAD2 radical S-adenosyl methionine domain containing 2 Blood + 3.81 0.000
9 IFI44L interferon-induced protein 44-like Blood + 3.58 0.000
10 USP41 ubiquitin specific peptidase 41 Blood + 3.40 0.000
11 HESX1 HESX homeobox 1 Blood + 3.22 0.000
12 IFIT3 interferon-induced protein with tetratricopeptide repeats 3 Blood + 3.08 0.000
Search GEO for disease gene expression data for Systemic Lupus Erythematosus.

Pathways for Systemic Lupus Erythematosus

Pathways related to Systemic Lupus Erythematosus according to KEGG:

37
id Name Kegg Source Accession
1 Systemic lupus erythematosus hsa05322

Pathways related to Systemic Lupus Erythematosus according to GeneCards Suite gene sharing:

(show all 17)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.75 C4A C4B CD40LG CR1 CTLA4 FCGR2A
2
Show member pathways
12.25 CD40LG CTLA4 IL10 PDCD1
3 12.25 CD40LG CTLA4 IL10 PDCD1 PTPN22 STAT4
4
Show member pathways
12.1 CD40LG CR1 FCGR2A FCGR3A IL10
5 12.05 CR1 FCGR2A FCGR2B FCGR3A IL10 TLR9
6
Show member pathways
11.81 IL10 STAT4 TLR5 TLR9
7
Show member pathways
11.77 C4A C4B CR1
8
Show member pathways
11.73 STAT4 TLR5 TLR9
9 11.69 FCGR2A FCGR2B FCGR3A
10 11.69 CR1 FCGR2A TLR5 TLR9
11 11.58 C4A C4B IL10
12 11.46 CD40LG CTLA4 PDCD1
13 11.43 CD40LG IL10 PDCD1 TNFSF4
14 11.36 CD40LG CR1 IL10 TLR9
15 11.34 IL10 STAT4 TNFSF4
16 11.18 C4A C4B FCGR2A FCGR2B FCGR3A IL10
17 11.17 CD40LG CR1 CTLA4 FCGR2A FCGR2B FCGR3A

GO Terms for Systemic Lupus Erythematosus

Cellular components related to Systemic Lupus Erythematosus according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 CD40LG CTLA4 FCGR3A PDCD1

Biological processes related to Systemic Lupus Erythematosus according to GeneCards Suite gene sharing:

(show all 20)
id Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.88 C4A C4B CR1 TLR5 TLR9 TRIM21
2 immune response GO:0006955 9.85 CD40LG CTLA4 FCGR2B FCGR3A IL10 TNFSF4
3 T cell costimulation GO:0031295 9.7 CD40LG CTLA4 PDCD1
4 regulation of type I interferon production GO:0032479 9.59 TREX1 TRIM21
5 response to molecule of bacterial origin GO:0002237 9.57 IL10 TLR9
6 histone mRNA metabolic process GO:0008334 9.55 SNRPB SSB
7 regulation of cytokine secretion GO:0050707 9.54 TLR5 TLR9
8 positive regulation of interleukin-12 production GO:0032735 9.5 CD40LG TLR9 TNFSF4
9 immune system process GO:0002376 9.5 C4A C4B CR1 CTLA4 PTPN22 TLR5
10 positive regulation of apoptotic cell clearance GO:2000427 9.49 C4A C4B
11 negative regulation of interleukin-8 production GO:0032717 9.48 IL10 TLR9
12 negative regulation of regulatory T cell differentiation GO:0045590 9.46 CTLA4 TNFSF4
13 positive regulation of toll-like receptor signaling pathway GO:0034123 9.43 TLR5 TLR9
14 positive regulation of interleukin-10 production GO:0032733 9.43 CD40LG TLR9 TNFSF4
15 regulation of innate immune response GO:0045088 9.28 PTPN22
16 negative regulation of immune response GO:0050777 9.27 CTLA4
17 negative regulation of cytokine secretion GO:0050710 9.26 TNFSF4
18 regulation of adaptive immune response GO:0002819 9.21 TNFSF4
19 inflammatory response GO:0006954 9.17 C4A C4B CD40LG IL10 TLR5 TLR9
20 negative regulation of B cell proliferation GO:0030889 9.16 CTLA4 IL10

Molecular functions related to Systemic Lupus Erythematosus according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 interleukin-1 receptor binding GO:0005149 8.96 TLR5 TLR9
2 IgG binding GO:0019864 8.8 FCGR2A FCGR2B FCGR3A

Sources for Systemic Lupus Erythematosus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....